"CRGderm" · Checked.be

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of "CRGderm" is 0.2% (very low). The 2025 annual accounts show equity of €149k and a net result of €31k. Equity is growing by ~32.2% per year across the filed fiscal years. Its solvency ranks better than 78% of 2217 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Signals

3 signals · with evidence

Strong solvency vs sector

Solvency is in the sector's strongest quartile: better than 78% of 2217 peers (2025). A comfortable equity buffer.

View the sector comparison

Consistently profitable

Positive net result in the two most recent financial years (2024 and 2025).

View the result trend

Growing equity

Equity grew over 2023-2025. Profits are largely retained rather than distributed.

View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-05-2026, 64 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

How we compute the deadline

The year end is derived from 3 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.

Deadline per financial year

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	28-05-2026	64 d early	2026-00126982
31-12-2024	31-07-2025	27-06-2025	34 d early	2025-00184671
31-12-2023	31-07-2024	08-07-2024	23 d early	2024-00218231

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals

More than 3 years active

Founded in 2022, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone

0.2% Very low

0%0,5%1,5%4%10%≥25%

Lower-failure-rate sector −Young company +Annual accounts: healthy financial profile −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)

EBIT marginNot published (abbreviated filing)

Net result€31k-30.4%

Working capital€135k+32.6%

CSV export

Annual accounts & ratios

Source: NBB · 2025

Annual accounts filed on 28-05-2026 with the NBB · fiscal year 2025 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Equity: growth of ~32.2%/year over 3 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (micro schema)

Metric	This company	Sector median	Position in the sector
Solvency	84.9%	58.2%	better than 78% of 2217 sector peers
Net result	€31k	€60k	better than 30% of 2215 sector peers
Equity	€149k	€74k	better than 69% of 2217 sector peers
Gross operating margin	€46k	€95k	better than 25% of 2217 sector peers
Total assets	€175k	€186k	better than 48% of 2217 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Sector position over time

Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).

Solvency P78

Improving position over 2023-2025 · n=2217-6582

Net result P30

Weakening position over 2023-2025 · n=2215-6576

Equity P69

Improving position over 2023-2025 · n=2217-6582

Gross operating margin P25

Weakening position over 2023-2025 · n=2217-6584

Describes the position versus peers, not a forecast.

EBITDA

€45k

-24.7% 23-25

Net profit

€31k

-30.4% 23-25

Cash flow

€35k

-23.8% 23-25

Total assets

€175k

+22.1% 23-25

Equity

€149k

+26.4% 23-25

Working capital

€135k

+32.6% 23-25

Income taxes

€8k

-29.7% 23-25

Debt

€26k

+2.6% 23-25

Show 8 other metrics

Debt ≤ 1y

€26k

+2.6% 23-25

Current ratio

6.13

+23.4% 23-25

Quick ratio

6.13

+23.4% 23-25

Solvency

84.9%

+3.5% 23-25

Debt / equity

0.18

-18.8% 23-25

ROE

20.9%

-45.0% 23-25

ROA

17.7%

-43.0% 23-25

Interest coverage

24.78

-10.6% 23-25

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2025
Deposit	micro
Revenue	-
EBITDA	€45k
Net profit	€31k
Cash flow	€35k
Staff costs	-
Income taxes	€8k
Dividends	-
Total assets	€175k
Equity	€149k
Debt	€26k
of which ≤ 1y	€26k
of which > 1y	-
Working capital	€135k
Employees (FTE)	-

Ratios (computed)

	2025
Current ratio	6.13
Quick ratio	6.13
Working capital ratio	77.3%
Solvency	84.9%
Debt / equity	0.18
Long-term debt ratio	-
Interest coverage	24.78
Gross margin	-
Net margin	-
ROA	17.7%
ROE	20.9%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2025

Assets

Fixed assets €13k · 7.6% Current assets €162k · 92.4%

Equity & liabilities

Equity €149k · 84.9% Debt €26k · 15.1%

Full annual accounts (21 line items)

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€175k
Fixed assets	21/28	€13k
Tangible fixed assets	22/27	€13k
Current assets	29/58	€162k
Amounts receivable within one year	40/41	€981
Cash & bank	54/58	€156k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€175k
Equity	10/15	€149k
Contributions / capital	10/11	€2k
Accumulated profits (losses)	14	€147k
Amounts payable	17/49	€26k
Amounts payable within one year	42/48	€26k
Trade debts payable within one year	44	€2k
Income statement
Gross operating margin	9900	€46k
Operating result	9901	€41k
Financial income	75	€3
Financial charges	65	€2k
Result before taxes	9903	€39k
Income taxes	67/77	€8k
Net result for the period	9904	€31k
Result to be appropriated	9905	€31k

This table shows the latest fiscal year. 2 prior years, with figures and ratios, belong to a paid plan. See plans →

Ratios computed by Checked.

Health barometer

FY 2025 · computed

93 / 100 Excellent

050100

Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →

Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

on the map · from the address register

exact location from the address register On OpenStreetMap

Establishment units

1 location

CRGderm

Rue de Marcinelle(NAL) 1, 6120 Ham-sur-Heure-NalinnesActiviteiten van medisch specialisten

since 20222.337.119.780

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Parcels2

Ground area5,335 m²

Buildings2

Building footprint505 m²

Volume (LiDAR)3,712 m³

Tallest building12.4 m · ±3 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Wallonia 2 (100%)